Targeting Neuroinflammation in Brain Cancer: Uncovering Mechanisms, Pharmacological Targets, and Neuropharmaceutical Developments.
Mahmoud S. Alghamri,Brandon L. McClellan,Margaret S. Hartlage,Santiago Haase,Syed M Faisal,Rohit Thalla,Ali Dabaja,Kaushik Banerjee,Stephen Carney,Anzar A. Mujeeb,Michael R. Olin,James J. Moon,Anna Schwendeman,Pedro R. Lowenstein,Maria G. Castro +14 more
Reads0
Chats0
TLDR
Glioblastomas are one of the most lethal types of cancers accounting for ~80% of all central nervous system (CNS) primary malignancies [1, as discussed by the authors.Abstract:
Gliomas are one of the most lethal types of cancers accounting for ~80% of all central nervous system (CNS) primary malignancies [1; 2]. Amongst gliomas, glioblastomas (GBM) are the most aggressive, characterized by a median patient survival of fewer than 15 months. Recent molecular characterization studies uncovered the genetic signatures and methylation status of gliomas and correlate these with clinical prognosis [2]. The most relevant molecular characteristics for the new glioma classification are IDH mutation, chromosome 1p/19q deletion, histone mutations, and other genetic parameters such as ATRX loss, TP53, and TERT mutations, as well as DNA methylation levels. Similar to other solid tumors, glioma progression is impacted by the complex interactions between the tumor cells and immune cells within the tumor microenvironment. The immune system’s response to cancer can impact the glioma’s survival, proliferation, and invasiveness. Salient characteristics of gliomas include enhanced vascularization, stimulation of a hypoxic tumor microenvironment, increased oxidative stress, and an immune suppressive milieu. These processes promote the neuro-inflammatory tumor microenvironment which can lead to the loss of blood-brain barrier (BBB) integrity. The consequences of a compromised BBB are deleteriously exposing the brain to potentially harmful concentrations of substances from the peripheral circulation, adversely affecting neuronal signaling, and abnormal immune cell infiltration; all of which can lead to disruption of brain homeostasis. In this review, we first describe the unique features of inflammation in CNS tumors. We then discuss the mechanisms of tumor-initiating neuro-inflammatory microenvironment and its impact on tumor invasion and progression. Finally, we also discuss potential pharmacological interventions that can be used to target neuro-inflammation in gliomas.read more
Citations
More filters
Journal ArticleDOI
RNA binding by ADAR3 inhibits adenosine-to-inosine editing and promotes expression of immune response protein MAVS
Reshma Raghava Kurup,Eimile Oakes,Aidan C. Manning,Priyanka Mukherjee,Pranathi Vadlamani,Heather A. Hundley +5 more
TL;DR: In this article , a global view of ADAR3-bound RNAs in glioblastoma cells and identifies both a role for ADAR-3 in repressing ADAR1-mediated editing and an RNA-binding dependent function of adar3 in regulating MAVS expression.
Journal ArticleDOI
Neuroinflammation and immunoregulation in glioblastoma and brain metastases: Recent developments in imaging approaches.
TL;DR: In this article, a review of recent advances in imaging methods that have helped to improve the specificity of primary tumor diagnosis versus evaluation of inflamed and necrotic brain lesions is presented.
Journal ArticleDOI
Dopamine, Immunity, and Disease
Breana Channer,Stephanie M. Matt,E. A. Nickoloff-Bybel,Vassiliki Pappa,Yash Agarwal,Jason R Wickman,Peter J. Gaskill +6 more
TL;DR: In this article , a review comprehensively assesses the current knowledge of dopaminergic immunology at the cellular, tissue, and disease level and prompts the development of therapeutics and strategies targeted toward ameliorating disease through dopamine regulation of immunity.
Journal ArticleDOI
Neuroinflammatory mediators in acquired epilepsy: an update
Yu Chen,Marwa M. Nagib,Nelufar Yasmen,Madison N. Sluter,Taylor L Littlejohn,Ying Yu,Jianxiong Jiang +6 more
Journal ArticleDOI
Metformin and Risk of Malignant Brain Tumors in Patients with Type 2 Diabetes Mellitus
TL;DR: The risk of malignant brain tumors associated with metformin use has rarely been investigated in humans as discussed by the authors, and the authors in this retrospective cohort study investigated such an association in humans.
References
More filters
Journal ArticleDOI
Perforin-mediated target-cell death and immune homeostasis
Ilia Voskoboinik,Ilia Voskoboinik,Mark J. Smyth,Mark J. Smyth,Joseph A. Trapani,Joseph A. Trapani +5 more
TL;DR: Recent progress is described in defining the structure, function, biochemistry and cell biology of perforin.
Journal Article
Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.
Michael B. Atkins,Michael J. Robertson,Michael S. Gordon,Michael T. Lotze,Michelle DeCoste,Jon S. Dubois,Jerome Ritz,Alan B. Sandler,Howard Edington,Pamela D. Garzone,James W. Mier,Christine Canning,Linda A. Battiato,Hideaki Tahara,Matthew L. Sherman +14 more
TL;DR: A Phase I dose escalation trial of recombinant human interleukin 12 (rhIL-12) was performed to determine its toxicity, maximum tolerated dose (MTD), pharmacokinetics, and biological and potential antineoplastic effects as discussed by the authors.
Journal ArticleDOI
Clinical use of dendritic cells for cancer therapy
TL;DR: The clinical effectiveness of dendritic cell-based vaccine therapy in melanoma, prostate cancer, malignant glioma, and renal cell carcinoma is reviewed, and the most important lessons from almost two decades of clinical studies are summarized.
Journal ArticleDOI
HER2-Specific Chimeric Antigen Receptor–Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial
Nabil Ahmed,Nabil Ahmed,Vita S. Brawley,Vita S. Brawley,Meenakshi Hegde,Meenakshi Hegde,Kevin Bielamowicz,Mamta Kalra,Daniel Landi,Daniel Landi,Catherine Robertson,Tara Gray,Oumar Diouf,Amanda Wakefield,Amanda Wakefield,Alexia Ghazi,Claudia Gerken,Claudia Gerken,Zhongzhen Yi,Zhongzhen Yi,Aidin Ashoori,Meng Fen Wu,Hao Liu,Cliona M. Rooney,Gianpietro Dotti,Adrian P. Gee,Adrian P. Gee,Jack Su,Yvonne Kew,David S. Baskin,Yi Jonathan Zhang,Pamela New,Bambi Grilley,Bambi Grilley,Milica Stojakovic,Milica Stojakovic,John Hicks,Suzanne Zein-Eldin Powell,Malcolm K. Brenner,Helen E. Heslop,Robert G. Grossman,Winfried S. Wels,Stephen Gottschalk +42 more
TL;DR: Investigation of whether the systemic administration of HER2-specific chimeric antigen receptor (CAR)–modified virus-specific T cells (VSTs) is safe and whether these cells have antiglioblastoma activity found them to be well tolerated.
Journal ArticleDOI
Tumor associated macrophages and neutrophils in cancer.
Maria Rosaria Galdiero,Eduardo Bonavita,Isabella Barajon,Cecilia Garlanda,Alberto Mantovani,Sébastien Jaillon +5 more
TL;DR: Macrophages and neutrophils are both integrated in the regulation of the innate and adaptive immune responses in various inflammatory situations, including cancer.